NCT04021862 - A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

November 19, 2020

Conditions

Atopic DermatitisEczema

Interventions

DRUG

Bermekimab Monoclonal Antibody

Bermekimab 400 mg or 800 mg will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Trial Locations (17)

23233

Dominion Medical Associates, Inc., Richmond

30328

Advanced Medical Research, Sandy Springs

32801

CNS HealthCare, Orlando

33134

Florida Academic Dermatology Centers, Coral Gables

33145

Floridian Research Institute, Miami

33155

Florida International Medical Research, Miami

33165

Premier Research Associate, Inc, Miami

33166

Doral Medical Research, Doral

33613

Avita Clinical Research, Tampa

Forcare Clinical Research Inc, Tampa

38358

Helios Clinical Research, LLC, Milan

43213

ClinOhio Research Services, Columbus

46256

Dawes Fretzin Clinical Research Group, Indianapolis

47906

Randall Dermatology & Cosmetic Surgery, West Lafayette

48084

Revival Research Institute LLC, Troy

78213

Progressive Clinical Research, San Antonio

92647

Beach Clinical Research Inc, Huntington Beach

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY